Midas Letter

RavenQuest BioMed Inc (CNSX:RQB) (OTCMKTS:RVVQF) (FRA:1IT) CEO George Robinson joins Midas Letter in-studio to discuss the company’s formal definitive agreement with Biocare partners for all RavenQuest’s joint venture operations located in Europe. The companies will construct cannabis cultivation facilities with planned capacity to produce 35,000 kilograms of medical cannabis initially in Portugal. The CEO also outlines the recent research partner announcement with McGill University. The license obtained from Health Canada allows for the possession and production of cannabis for research purposes. The CEO also explains the economics of the company’s trademark Orbital Garden technology, stating the company is in position to take a run at anyone in terms of cost and efficiency.

So I think what you’re going to see over the next six months is really, really good. Hitting our targets for our deliverables on cannabis sales, hitting our numbers on the consulting side as we look outside of Canada, and then you take a lot at more prospectively on what we’re going to do to actually make a very interesting company and take that technology and leverage it on a worldwide basis. That’s what’s really exciting right now, and I think most of the world has woken up to orbital gardening strategies versus a flat table environment. – George Robinson, RavenQuest BioMed CEO

Original article: RavenQuest BioMed Inc (CNSX:RQB) Industry Leading Grow Technology & Formalizing European Operations©2019 Midas Letter. All Rights Reserved.

CB2 Insights Inc (CNSX:CBII) (OTCMKTS:CBIIF) CEO Prad Sekar joins Midas Letter to discuss strengthening the company’s presence in the UK medical cannabis market with MyAccess Clinics tie-up. CB2 Insights specialize in clinical trials for companies that want to develop medicine in a range of therapeutic areas. CB2 service over 100,000 patients a year which operates as a profitable business. Those profits then go to fund commercializing further technology and research. With the company’s latest news, CB2 will provide MyAccess Clinics its software within multi-clinic operation in the UK for data input and management. 

Original article: CB2 Insights (CNSX:CBII) on Launching Patient Data Management Software in UK©2019 Midas Letter. All Rights Reserved.

Khiron Life Sciences Corp (TSX-V:KHRN) (OTCQB:KHRNF) CEO Alvaro Torres joins Midas Letter to discuss completing the construction of their sophisticated medical cannabis processing facility and its capacity to produce commercial products. The GMP certified lab has microbiology and physical chemical analysis labs and also extraction capacity. Through scalable and flexible operations, Khiron has designed its cultivation capabilities to work within the most up-to-date country quota to meet Colombian demand, including serving more than 120,000 patients at the Company’s IILANS clinics. The CEO also comments on construction of its Uruguay facility, which will act as an entryway to the Brazilian market.

Addressing the underwhelming financial performance of cannabis companies this quarter, the Khiron CEO comments:

“we all have to understand that this is a difficult market to begin. But we’ve been doing this for only a year and a half; we’re already generating $5 million in sales for the first half of the year, with the clinics and with Kuida.”

Original article: Khiron Life Sciences (CVE:KHRN) on Meeting UN Quotas to Supply Colombian Clinics©2019 Midas Letter. All Rights Reserved.

Green Relief CEO Neilank Jha joins James West and Chris Geiser to talk CBD and the relationship with professional sports and the application to pain management. There are more scientific reports and sporting figures getting behind the beneficial effects of cannabinoids. The natural compounds of hemp are starting to reevaluated by the largest sporting organizations where the compound is currently on the banned substance lists. Green relief are creating awareness to the potential benefits of using cannabis to alleviate symptoms related to pain and exercise recovery. The CEO also outlines the company’s shift from cultivation to extraction and processing and intellectual property.

Original article: Green Relief CEO Dr Neilank Jha on CBD Recovery in Sport©2019 Midas Letter. All Rights Reserved.

RavenQuest BioMed Inc’s (CNSX:RQB) (OTCMKTS:RVVQF) (FRA:1IT) Mathieu McDonald joins Midas Letter to discuss the company’s cannabis plant research at McGill University to produce consistent cannabis at a low cost. The agreement with McGill University studies methodologies behind cannabis plant stabilization and yield maximization. Mr. McDonald also discusses the company’s Cannabis Biocare joint-venture, which will provide full funding for facility build-outs and the company’s revolutionary Orbital Garden technologies globally. Initial production will focus upon Portugal and European expansion into East Africa, West Africa and the Middle East. Discussing the company’s growing technology in comparison to the industry standard green house growing operations, Mathieu McDonald states “We fit 500 square foot of row space on that, using 65% less power, 90% less nutrients and dripping 0 water to waste.”

Original article: RavenQuest BioMed (CNSX:RQB) Producing Consistent Cannabis at Low Cost©2019 Midas Letter. All Rights Reserved.

Trulieve Cannabis Corp (CNSX:TRUL) (OTCMKTS:TCNNF) CEO Kim Rivers joins Midas Letter to discuss the story behind the Florida-based cannabis company. On top of cultivating, producing and distributing all of its products in dispensaries and home delivery throughout the State of Florida, Trulieve also operates in California, Massachusetts and Connecticut. Ms. Rivers is Florida’s first leader of a leading medical cannabis company.  As CEO, Ms. Rivers directed the construction of the company’s cultivation and processing facilities. and created Trulieve’s Florida dispensary network. Over the course of her tenure, Ms. Rivers has negotiated acquisition terms of multiple licenses and licensing arrangements in multiple states with national cannabis brands, including recent acquisitions in California and Massachusetts.

Original article: 30 Minutes with Trulieve Cannabis Corp (CNSX:TRUL) CEO Kim Rivers©2019 Midas Letter. All Rights Reserved.

Organigram Holdings Inc (TSE:OGI) (NASDAQ:OGI) CEO Greg Engel joins Midas Letter to discuss the company’s strong fundamentals as the cannabis sector is down over 50 percent.

“We’ve had four quarters now consecutively with positive adjusted EBITDA, and we’re certainly seeing a shift to large institutional funds that are looking at more fundamentals” – Organigram Holdings Inc CEO Greg Engel

The CEO highlights the company’s strong gross margin and balance sheet while outlining their strategic commitment to growth in the edible and derivative-based product market. Organigram are one of four companies with a partnership with PAX; a leading consumer technology brand in the design and development of premium vaporizers for dry flower and concentrates. With concentrates due to become legal in Canada later this year. In terms of edibles, Organigram are focused on high-speed, high-capacity, fully-automated production line of chocolates having invested $15 million in Ganong Bros Limited. The investment has the ability to produce an estimated 4 million kilograms of chocolate cannabis edibles per year. Lastly, the company is focusing on a unique dried powder dissolvable beverage isolate stable for both CBD and THC. The dissolvable powder will allow consumers to add their favourite marijuana molecules to their beverage of choice.

Original article: Organigram Holdings Inc (TSE:OGI) Future Growth into Edible and Derivative Cannabis Market©2019 Midas Letter. All Rights Reserved.

Khiron Life Sciences Corp (TSX-V:KHRN) (OTCQB:KHRNF) joins Midas Letter on Skype from his office in Bogota, Colombia to discuss his outlook for the company in the next few quarters. Khiron’s revenue has been growing, reporting an adjusted EBITDA of 7.7 million, and will expand its income statement as the company will begin medical cannabis sales within the next six months. Patients living in Colombia should be able to start enjoying shipments of Khiron medical products before the end of the calendar year pending just a couple more regulatory hurdles. Khiron’s Kuida cosmeceutical product line is also increasing its distribution across different retail networks. Most recently, Khiron’s 50/50 joint-venture with Dixie Brands Inc (CSE:DIXI.U) (OTCQX:DXBRF) received conditional TSX-Venture exchange approval allowing for the commercialization of the Kuida products in the U.S. market. Khiron have advantages in the cannabis market with the lower-cost of running a cannabis company based out of Colombia coupled with the company’s progress in Europe and the rest of Latin American like Mexico, Brazil and Argentina. For these reasons, the CEO sees Khiron exceeding the expectations of a consensus of six different analysts indicating that the company’s projected profit in 2021 will be at least $6.1 million.

Original article: Khiron Life Sciences (CVE:KHRN) Expanded Retail Presence and Latin American Growth©2019 Midas Letter. All Rights Reserved.

African Gold Group, Inc (TSX-V: AGG) Chairman and CEO Stan Bharti joins Midas Letter to outline the big uptick in the gold price and how the trend effects junior gold mining and the company. African Gold Group is developing a gold platform in West Africa with its principal asset being the Kobada Project in southern Mali. The official resource in Kobada is 2 million ounces, but the CEO sees the potential for a far greater resource. The economics were calculated at a gold price of $1,200 with a rate of return of almost 50 percent and a one-and-a-half-year payback. At the current $1,500 gold price level, those numbers dramatically improve as the current cost for AGG is under $600 per ounce. Mr Bharti explains “we’re going to start small, because the gold market is still starting; we’ll start at 50,000 ounces. The vision is to expand gradually to 100,000 to 150,000 ounces, depending on exploration results.” The CEO also outlines the several private placements the company have under taken in recent months – the latest for gross proceeds of approximately $3 million.

Should I buy gold? Should I buy ETFs? Should I buy majors? And the answer is, buy junior gold stocks, because they will give you the most leverage. If you want a 10X return, buy junior gold stocks. – Stan Bharti, African Gold Group CEO

Original article: African Gold Group (CVE:AGG) CEO on New Financing Rounds and Recent Stock Surge©2019 Midas Letter. All Rights Reserved.

Canopy Rivers Inc (CVE:RIV) (OTCMKTS:CNPOF) CEO Narbe Alexandrian joins Midas Letter to discuss the company’s value proposition for investors to avail themselves of venture capital firm level due diligence while investing in a portfolio of cannabis companies. The CEO likens the investment to an Exchange-Traded Fund (ETF), however Canopy Rivers also are able to invest into private companies at multiples lower than companies already trading in public markets. Mr Alexandrian states he “can proudly say that I don’t think any other venture fund out there within the cannabis space looks at as many deals as us.” In the last year Canopy Rivers, with its merchant bank type of structure in the cannabis space, have seen 1,523 pitches to date. The company looks to invest in all segments of the cannabis value chain and currently have eighteen companies in its portfolio. The recent purchase and supply agreements between portfolio companies James E. Wagner Cultivation Corp (JWC) and TerrAscend Corp demonstrates the collaboration and synergy that can happen within their investment ecosystem. The CEO also discusses his views on the future of the cannabis sector and what that means for Canopy Rivers future deal flow.

Original article: Canopy Rivers Inc (CVE:RIV) Horizontally Integrated Investment Ecosystem©2019 Midas Letter. All Rights Reserved.